Learn more about recently approved Hemgenix in the treatment of Hemophilia B, the gene therapy pipeline, the approval process, and what gene therapies are, in our second edition of the Introduction to Gene Therapies paper.
Managing Self-funded Risk
February 06, 2023
Introduction to Gene Therapies (3rd edition)
September 29, 2022
Impacts of Blood Cancer: Blood Cancer was the #2 high-cost claims condition and nearly 10% of 2021 total spend within Sun Life’s Health & Risk Solutions book of business
Every three minutes, someone in the U.S. is diagnosed with blood cancer.
June 22, 2022
2022 Sun Life Stop-Loss Research Report: High-cost claims and injectable drug trends analysis
For the past ten years, Sun Life has shared our data and insights with the self-funded marketplace to help employers and brokers understand trends around the highest-cost claims.
June 08, 2022
Webinar: 2022 High-cost claims and injectable drug trends analysis
A presentation and panel discussion on our high-cost claims and injectable drug trends analysis with insights on top claim conditions, million-dollar claims, injectable drugs, and trends we are seeing since the COVID-19 pandemic began.
June 08, 2021
Webinar: 2021 High-cost claims and injectable drug trends analysis
A presentation and panel discussion on our annual Stop-Loss high-cost claims and injectable drugs trends analysis, the impact of COVID-19, million-dollar claims and more!
May 24, 2021
Group stop-loss captives: A path to self-funding
Learn about the rising interest in self-funding and how employers of many sizes can transition to self-funding with group stop-loss captives.
June 30, 2020
Million-dollar claim cost drivers and legislative updates
A look inside Sun Life’s most recent million-dollar claim and injectable drug trend analysis with legislative updates on issues impacting self-funded employers.
June 01, 2020
2020 Sun Life Stop-Loss Research Report
June 01, 2019
2019 Sun Life Stop-Loss Research Report: High-cost claims and injectable drug trends
June 01, 2018